Comparison of the clinical performance of an HPV mRNA test and an HPV DNA test in triage of atypical squamous cells of undetermined significance (ASC-US)

Cytopathology

Volumn 23, Issue 6, 2012, Pages 389-395

  Waldstrom, M ^a   Ornskov, D ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

Author keywords

Aptima; ASC US; E6 E7 mRNA; HPV DNA; Linear Array; Liquid based cytology triage; Oncogenic human papillomavirus

Indexed keywords

MESSENGER RNA; VIRUS DNA;

ADULT; ARTICLE; ATYPICAL SQUAMOUS CELL OF UNDERTERMINED SIGNIFICANCE; CANCER GRADING; CONTROLLED STUDY; CYTOLOGY; DISEASE SEVERITY; EMERGENCY HEALTH SERVICE; ENDOMETRIUM CYTOLOGY; FEMALE; FOLLOW UP; GENOTYPE; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIQUID BASED CYTOLOGY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SENSIBILITY; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CARCINOGENESIS; VIRUS DETECTION; WART VIRUS;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CONFIDENCE INTERVALS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RNA, MESSENGER; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TRIAGE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84870251815     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/j.1365-2303.2011.00923.x     Document Type: Article

References (22)

1. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
2. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. J Natl Cancer Inst 2000;92:397-402.
3. Jordan J, Arbyn M, Martin-Hirsch P et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology 2008;19:342-54.
4. Solomon D, Papillo JL, Davey DD. Statement on HPV DNA test utilization. Diagn Cytopathol 2009;37:542-3.
5. Arbyn M, Sasieni P, Meijer CJ et al. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24:S3-78.
6. Safaeian M, Solomon D, Wacholder S, Schiffman M, Castle P. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance. Obstet Gynecol 2007;109:1325-31.
7. Kjaer SK, Breugelmans G, Munk C et al. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 2008;123:1864-70.
8. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007;195:1582-9.
9. Szarewski A, Ambroisine L, Cadman L et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008;17:3033-42.
10. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of Cervical Intraepithelial Neoplasia Grade 3 or worse following human papillomavirus infection: role of Persistence. J Natl Cancer Inst 2010;102:1478-88.
11. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006;110:525-41.
12. Molden T, Nygard JF, Kraus I et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 2005;114:973-6.
13. Reuschenbach M, Clad A, Von Knebel DC et al. Performance of p16(INK4a)-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. Gynecol Oncol 2010;119:98-105.
14. Ratnam S, Coutlee F, Fontaine D et al. Clinical performance of the pretect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol 2010;48:2779-85.
15. Halfon P, Benmoura D, Agostini A et al. Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPV assay. J Clin Virol 2010;47:177-81.
16. Chase DM, Kalouyan M, DiSaia PJ. Colposcopy to evaluate abnormal cervical cytology in 2008. Am J Obstet Gynecol 2009;200:472-80.
17. Carreon JD, Sherman ME, Guillen D et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 2007;26:441-6.
18. Halfon P, Benmoura D, Khiri H et al. Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck HPV-screening assay. J Clin Virol 2010;47:38-42.
19. Gravitt PE, Schiffman M, Solomon D, Wheeler CM, Castle PE. A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Cancer Epidemiol Biomarkers Prev 2008;17:1248-54.
20. Geisinger KR, Vrbin C, Grzybicki DM et al. Interobserver variability in human papillomavirus test results in cervicovaginal cytologic specimens interpreted as atypical squamous cells. Am J Clin Pathol 2007;128:1010-14.
21. Dockter J, Schroder A, Hill C et al. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol 2009;45:S55-61.
22. Stevens MP, Garland SM, Rudland E et al. Comparison of the Digene Hybrid Capture 2 assay and Roche Amplicor and Linear Array human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal pap smear results. J Clin Microbiol 2007;45:2130-7.